Development of immunotherapeutic strategies for the treatment of malignant neoplasia.

Research output: Contribution to journalReview article

Abstract

The utility of biologics and BRMs in cancer therapeutics can be considered with a cautious optimism predicated on the progress that has occurred to date and the specific indications that can now be identified. Although to date BRMs have shown only limited activity in restricted subsets of patients which may be viewed as dissuasion to some investigators; nonetheless, it should also be a stimulus to conduct careful, basic, and clinical experimentation aimed at verifying the promise from preclinical studies and to obtain further fundamental information on the BRM mechanism of action that would provide a basis for the ultimate utilization of these agents as well as the identification-development of appropriate analogs predicted on the deficiencies observed to date with the BRM.

Original languageEnglish (US)
Pages (from-to)250-275
Number of pages26
JournalPathology and immunopathology research
Volume8
Issue number5-6
DOIs
StatePublished - Jan 1 1989

Fingerprint

Biological Products
Research Personnel
Neoplasms
Therapeutics
Optimism

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Development of immunotherapeutic strategies for the treatment of malignant neoplasia. / Talmadge, James E.

In: Pathology and immunopathology research, Vol. 8, No. 5-6, 01.01.1989, p. 250-275.

Research output: Contribution to journalReview article

@article{335a7016629345b1bcfc9b388196ece7,
title = "Development of immunotherapeutic strategies for the treatment of malignant neoplasia.",
abstract = "The utility of biologics and BRMs in cancer therapeutics can be considered with a cautious optimism predicated on the progress that has occurred to date and the specific indications that can now be identified. Although to date BRMs have shown only limited activity in restricted subsets of patients which may be viewed as dissuasion to some investigators; nonetheless, it should also be a stimulus to conduct careful, basic, and clinical experimentation aimed at verifying the promise from preclinical studies and to obtain further fundamental information on the BRM mechanism of action that would provide a basis for the ultimate utilization of these agents as well as the identification-development of appropriate analogs predicted on the deficiencies observed to date with the BRM.",
author = "Talmadge, {James E}",
year = "1989",
month = "1",
day = "1",
doi = "10.1159/000157155",
language = "English (US)",
volume = "8",
pages = "250--275",
journal = "Pathology and immunopathology research",
issn = "0257-2761",
publisher = "S. Karger AG",
number = "5-6",

}

TY - JOUR

T1 - Development of immunotherapeutic strategies for the treatment of malignant neoplasia.

AU - Talmadge, James E

PY - 1989/1/1

Y1 - 1989/1/1

N2 - The utility of biologics and BRMs in cancer therapeutics can be considered with a cautious optimism predicated on the progress that has occurred to date and the specific indications that can now be identified. Although to date BRMs have shown only limited activity in restricted subsets of patients which may be viewed as dissuasion to some investigators; nonetheless, it should also be a stimulus to conduct careful, basic, and clinical experimentation aimed at verifying the promise from preclinical studies and to obtain further fundamental information on the BRM mechanism of action that would provide a basis for the ultimate utilization of these agents as well as the identification-development of appropriate analogs predicted on the deficiencies observed to date with the BRM.

AB - The utility of biologics and BRMs in cancer therapeutics can be considered with a cautious optimism predicated on the progress that has occurred to date and the specific indications that can now be identified. Although to date BRMs have shown only limited activity in restricted subsets of patients which may be viewed as dissuasion to some investigators; nonetheless, it should also be a stimulus to conduct careful, basic, and clinical experimentation aimed at verifying the promise from preclinical studies and to obtain further fundamental information on the BRM mechanism of action that would provide a basis for the ultimate utilization of these agents as well as the identification-development of appropriate analogs predicted on the deficiencies observed to date with the BRM.

UR - http://www.scopus.com/inward/record.url?scp=0024839712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024839712&partnerID=8YFLogxK

U2 - 10.1159/000157155

DO - 10.1159/000157155

M3 - Review article

VL - 8

SP - 250

EP - 275

JO - Pathology and immunopathology research

JF - Pathology and immunopathology research

SN - 0257-2761

IS - 5-6

ER -